436 Studies Now Enrolling
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-TreatmentArm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401in Subjects With Preclinical Alzheimers Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimers Disease and Intermediate Amyloid (A3 Trial)
Study of BAN2401 in Subjects with Preclinical Alzheimer's Disease
| Sponsor: | Eisai Inc. |
| Enrolling: | Male and Female Patients |
| Study Length: | 4 Years |
| IRB Number: | AAAT3026 |
| U.S. Govt. ID: | NCT04468659 |
| Contact: | Chrismary De La Cruz: 212-305-7661 / cd3097@cumc.columbia.edu |
Additional Study Information:
We are seeking men & women, ages 55 to 80, who have preclinical Alzheimer's disease for a 216-week treatment, multi-center, double-blind, placebo-controlled, parallel-treatment arm study to determine whether the BAN2401 study drug will reduce the risk of developing Alzheimer's disease. The study participant will receive MRI, and PET scans and will receive intravenous study drug or placebo every 2 weeks.
This study is closed
